From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL-2/BCL-XL...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Simultaneous blockade of anti-apoptotic proteins BCL-2 and BCL-XL is effective in preclinical and clinical cancer trials.
• Clinical development is hindered by dose-limiting thrombocytopenia from BCL-XL inhibition.

Purpose of the Study:

• To explore strategies for separating anti-tumor activity from platelet toxicity in dual BCL-2/BCL-XL inhibitors.
• To integrate mechanistic rationale, preclinical data, and clinical evidence for novel therapeutic approaches.
• To propose future directions for developing safe and active dual BCL-2/BCL-XL therapies.

Main Methods:

• Targeted protein degraders (PROTACs) to spare platelet BCL-XL.
• Prodrug and formulation strategies for preferential tumor drug delivery.
• Optimized dosing and scheduling for durable mechanisms of action.
• Rational combination regimens to reduce per-agent exposure.

Main Results:

• Emerging strategies aim to mitigate thrombocytopenia while maintaining anti-tumor efficacy.
• Preclinical and clinical evidence supports the feasibility of these complementary approaches.
• These developments offer a pathway to safer and more broadly applicable dual BCL-2/BCL-XL inhibitors.

Conclusions:

• New strategies present an opportunity to develop dual BCL-2/BCL-XL inhibitors with enhanced anti-tumor activity.
• Minimizing thrombocytopenia is key to broadening the clinical application of these targeted therapies.
• Further research and clinical exploration are warranted to optimize these approaches.